CL2017002498A1 - Piridopirimidinonas y su uso como modulares del receptor nmda - Google Patents
Piridopirimidinonas y su uso como modulares del receptor nmdaInfo
- Publication number
- CL2017002498A1 CL2017002498A1 CL2017002498A CL2017002498A CL2017002498A1 CL 2017002498 A1 CL2017002498 A1 CL 2017002498A1 CL 2017002498 A CL2017002498 A CL 2017002498A CL 2017002498 A CL2017002498 A CL 2017002498A CL 2017002498 A1 CL2017002498 A1 CL 2017002498A1
- Authority
- CL
- Chile
- Prior art keywords
- pyridopyrimidinones
- modulators
- nmda receptor
- compounds
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
<p>La invención se refiere a compuestos piridopirimidinona de fórmula I: o sales farmacéuticamente aceptables de los mismos, en los que X, R1 , R2 , R3 , R4 , R5 y R6 son tal como se define en la presente memoria, así como composiciones farmacéuticas que comprenden dichos compuestos y métodos de tratamiento que utilizan dichos compuestos.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015076617 | 2015-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002498A1 true CL2017002498A1 (es) | 2018-04-20 |
Family
ID=55809078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002498A CL2017002498A1 (es) | 2015-04-15 | 2017-10-03 | Piridopirimidinonas y su uso como modulares del receptor nmda |
Country Status (20)
Country | Link |
---|---|
US (1) | US10280165B2 (es) |
EP (1) | EP3283487B1 (es) |
JP (2) | JP6847851B2 (es) |
KR (1) | KR20170137137A (es) |
CN (1) | CN107531696B (es) |
AU (1) | AU2016248886B2 (es) |
BR (1) | BR112017021083A2 (es) |
CA (1) | CA2982217A1 (es) |
CL (1) | CL2017002498A1 (es) |
CO (1) | CO2017009989A2 (es) |
CR (1) | CR20170462A (es) |
HK (1) | HK1245259A1 (es) |
IL (1) | IL254921B (es) |
MX (1) | MX2017013101A (es) |
PE (1) | PE20180316A1 (es) |
PH (1) | PH12017501876A1 (es) |
RU (1) | RU2717665C2 (es) |
SG (1) | SG11201708294YA (es) |
UA (1) | UA120647C2 (es) |
WO (1) | WO2016166078A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2926830C (en) | 2013-10-11 | 2023-08-01 | F. Hoffmann-La Roche Ag | Thiazolopyrimidinones as modulators of nmda receptor activity |
EP3283487B1 (en) | 2015-04-15 | 2019-10-16 | H. Hoffnabb-La Roche Ag | Pyridopyrimidinones and their use as nmda receptor modulators |
AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
PE20210948A1 (es) | 2018-08-03 | 2021-05-24 | Cadent Therapeutics Inc | Moduladores del receptor nmda heteroaromatico y usos de los mismos |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
US7326711B2 (en) * | 2003-06-20 | 2008-02-05 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
CA2677493A1 (en) * | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
KR101811549B1 (ko) * | 2013-06-19 | 2017-12-26 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체 |
CA2926830C (en) | 2013-10-11 | 2023-08-01 | F. Hoffmann-La Roche Ag | Thiazolopyrimidinones as modulators of nmda receptor activity |
EP3283487B1 (en) | 2015-04-15 | 2019-10-16 | H. Hoffnabb-La Roche Ag | Pyridopyrimidinones and their use as nmda receptor modulators |
-
2016
- 2016-04-12 EP EP16718618.8A patent/EP3283487B1/en active Active
- 2016-04-12 CR CR20170462A patent/CR20170462A/es unknown
- 2016-04-12 CA CA2982217A patent/CA2982217A1/en not_active Abandoned
- 2016-04-12 CN CN201680021960.3A patent/CN107531696B/zh active Active
- 2016-04-12 MX MX2017013101A patent/MX2017013101A/es active IP Right Grant
- 2016-04-12 BR BR112017021083-5A patent/BR112017021083A2/pt not_active IP Right Cessation
- 2016-04-12 KR KR1020177032061A patent/KR20170137137A/ko not_active Application Discontinuation
- 2016-04-12 JP JP2017553877A patent/JP6847851B2/ja active Active
- 2016-04-12 UA UAA201711077A patent/UA120647C2/uk unknown
- 2016-04-12 RU RU2017139254A patent/RU2717665C2/ru active
- 2016-04-12 WO PCT/EP2016/057962 patent/WO2016166078A1/en active Application Filing
- 2016-04-12 SG SG11201708294YA patent/SG11201708294YA/en unknown
- 2016-04-12 AU AU2016248886A patent/AU2016248886B2/en not_active Ceased
- 2016-04-12 PE PE2017002006A patent/PE20180316A1/es unknown
-
2017
- 2017-09-29 CO CONC2017/0009989A patent/CO2017009989A2/es unknown
- 2017-10-03 CL CL2017002498A patent/CL2017002498A1/es unknown
- 2017-10-08 IL IL254921A patent/IL254921B/en active IP Right Grant
- 2017-10-13 US US15/783,373 patent/US10280165B2/en active Active
- 2017-10-13 PH PH12017501876A patent/PH12017501876A1/en unknown
-
2018
- 2018-04-09 HK HK18104623.7A patent/HK1245259A1/zh unknown
-
2020
- 2020-12-03 JP JP2020200946A patent/JP2021046428A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20170462A (es) | 2018-02-01 |
EP3283487A1 (en) | 2018-02-21 |
PH12017501876A1 (en) | 2018-02-26 |
CO2017009989A2 (es) | 2018-01-05 |
CN107531696B (zh) | 2021-03-16 |
MX2017013101A (es) | 2018-01-30 |
HK1245259A1 (zh) | 2018-08-24 |
UA120647C2 (uk) | 2020-01-10 |
SG11201708294YA (en) | 2017-11-29 |
RU2017139254A3 (es) | 2019-09-30 |
WO2016166078A1 (en) | 2016-10-20 |
KR20170137137A (ko) | 2017-12-12 |
BR112017021083A2 (pt) | 2018-07-03 |
RU2017139254A (ru) | 2019-05-15 |
RU2717665C2 (ru) | 2020-03-24 |
IL254921B (en) | 2021-02-28 |
EP3283487B1 (en) | 2019-10-16 |
JP6847851B2 (ja) | 2021-03-24 |
JP2018511627A (ja) | 2018-04-26 |
CA2982217A1 (en) | 2016-10-20 |
US10280165B2 (en) | 2019-05-07 |
AU2016248886B2 (en) | 2020-09-10 |
PE20180316A1 (es) | 2018-02-09 |
IL254921A0 (en) | 2017-12-31 |
JP2021046428A (ja) | 2021-03-25 |
CN107531696A (zh) | 2018-01-02 |
US20180127414A1 (en) | 2018-05-10 |
AU2016248886A1 (en) | 2017-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018007443A2 (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CL2017003205A1 (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
SV2017005590A (es) | Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
CR20170590A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CR20160518A (es) | Compuestos para tratar atrofia muscular espinal | |
SV2017005381A (es) | Compuestos de imidazopiridazina | |
ECSP17069696A (es) | Compuestos novedosos | |
PH12017501280A1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
UY36110A (es) | Inhibidores de quinasa relacionados con tropomiosina | |
EA201600619A1 (ru) | Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы | |
CR20160084A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico | |
ECSP16096831A (es) | Derivados de naftiridinadiona | |
ECSP16074482A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
ECSP18056196A (es) | Derivados de indano | |
EA201600032A1 (ru) | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина | |
SV2014004879A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen |